BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 15246074)

  • 1. CoMFA and CoMSIA 3D QSAR analysis on N1-arylsulfonylindole compounds as 5-HT6 antagonists.
    Doddareddy MR; Cho YS; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Aug; 12(15):3977-85. PubMed ID: 15246074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A 3D-QSAR CoMSIA study on 3-azolylmethylindoles as anti-leishmanial agents.
    Giraud F; Loge C; Le Borgne M; Pagniez F; Na YM; Le Pape P
    SAR QSAR Environ Res; 2006 Jun; 17(3):299-309. PubMed ID: 16815769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 3D QSAR studies on T-type calcium channel blockers using CoMFA and CoMSIA.
    Doddareddy MR; Jung HK; Cha JH; Cho YS; Koh HY; Chang MH; Pae AN
    Bioorg Med Chem; 2004 Apr; 12(7):1613-21. PubMed ID: 15028254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
    Pandey G; Saxena AK
    J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists.
    Doddareddy MR; Lee YJ; Cho YS; Choi KI; Koh HY; Pae AN
    Bioorg Med Chem; 2004 Jul; 12(14):3815-24. PubMed ID: 15210148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents.
    Bhongade BA; Gadad AK
    Bioorg Med Chem; 2004 May; 12(10):2797-805. PubMed ID: 15110861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
    Bhongade BA; Gadad AK
    J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 3D-QSAR CoMFA/CoMSIA studies on 5-aryl-2,2-dialkyl-4-phenyl-3(2H)-furanone derivatives, as selective COX-2 inhibitors.
    Puntambekar DS; Giridhar R; Yadav MR
    Acta Pharm; 2006 Jun; 56(2):157-74. PubMed ID: 16613723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Three-dimensional quantitative structure-activity relationship study for phenylsulfonyl carboxylates using CoMFA and CoMSIA.
    Liu X; Yang Z; Wang L
    Chemosphere; 2003 Dec; 53(8):945-52. PubMed ID: 14505717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-dimensional quantitative structure-activity relationship (3D-QSAR) analyses of choline acetyltransferase inhibitors.
    Chandrasekaran V; McGaughey GB; Cavallito CJ; Bowen JP
    J Mol Graph Model; 2004 Sep; 23(1):69-76. PubMed ID: 15331055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3D-QSAR CoMFA/CoMSIA models based on theoretical active conformers of HOE/BAY-793 analogs derived from HIV-1 protease inhibitor complexes.
    da Cunha EF; Sippl W; de Castro Ramalho T; Ceva Antunes OA; de Alencastro RB; Albuquerque MG
    Eur J Med Chem; 2009 Nov; 44(11):4344-52. PubMed ID: 19616874
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the antitumor activity of novel tricyclicpiperazinyl derivatives as farnesyltransferase inhibitors using CoMFA and CoMSIA.
    Puntambekar DS; Giridhar R; Yadav MR
    Eur J Med Chem; 2006 Nov; 41(11):1279-92. PubMed ID: 16919851
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 3D-QSAR studies on malonyl coenzyme A decarboxylase inhibitors.
    Patel MR; Talele TT
    Bioorg Med Chem; 2007 Jul; 15(13):4470-81. PubMed ID: 17482825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure-based 3D-QSAR studies on heteroarylpiperazine derivatives as 5-HT3 receptor antagonists.
    Zhou YJ; Zhu LP; Tang Y; Ye DY
    Eur J Med Chem; 2007 Jul; 42(7):977-84. PubMed ID: 17331624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantitative structure-activity relationships for a series of inhibitors of cruzain from Trypanosoma cruzi: molecular modeling, CoMFA and CoMSIA studies.
    Trossini GH; Guido RV; Oliva G; Ferreira EI; Andricopulo AD
    J Mol Graph Model; 2009 Aug; 28(1):3-11. PubMed ID: 19376735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative molecular field analysis and comparative molecular similarity indices analysis of human thymidine kinase 1 substrates.
    Bandyopadhyaya AK; Johnsamuel J; Al-Madhoun AS; Eriksson S; Tjarks W
    Bioorg Med Chem; 2005 Mar; 13(5):1681-9. PubMed ID: 15698786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators.
    Labrie P; Maddaford SP; Fortin S; Rakhit S; Kotra LP; Gaudreault RC
    J Med Chem; 2006 Dec; 49(26):7646-60. PubMed ID: 17181148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 3D-QSAR studies of boron-containing dipeptides as proteasome inhibitors with CoMFA and CoMSIA methods.
    Zhu YQ; Lei M; Lu AJ; Zhao X; Yin XJ; Gao QZ
    Eur J Med Chem; 2009 Apr; 44(4):1486-99. PubMed ID: 18771818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors.
    Lu P; Wei X; Zhang R
    Eur J Med Chem; 2010 May; 45(5):1792-8. PubMed ID: 20149491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies.
    Hou T; Zhu L; Chen L; Xu X
    J Chem Inf Comput Sci; 2003; 43(1):273-87. PubMed ID: 12546563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.